<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678403</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/14/7386</org_study_id>
    <secondary_id>2015-A01534-45</secondary_id>
    <nct_id>NCT02678403</nct_id>
  </id_info>
  <brief_title>Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI</brief_title>
  <acronym>TENS-PAD</acronym>
  <official_title>Efficacy of Transcutaneous Electrical Nerve Stimulation in the Improvement of Walking Distance in Patients With Peripheral Artery Disease With Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The investigators team recently carried out a proof of concept study testing the&#xD;
      efficacy of one single 45-minute session of 10 Hz TENS prior to walking, versus placebo. In&#xD;
      this randomized study, the investigators found that TENS significantly delayed pain onset and&#xD;
      increased the pain-free walking distance in patients with class II PAD. From these&#xD;
      encouraging results, the investigators now seek to assess the efficacy of an intervention&#xD;
      that includes the daily use of TENS for 3 weeks (5 days a week) on walking distance in PAD&#xD;
      (Leriche-Fontaine stage II). Methods/Design: prospective multicentre study / randomized&#xD;
      controlled trial / double blinding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventions (2 groups): Experimental group (TENS group): the treatment will consist of&#xD;
      stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal&#xD;
      intensity below motor threshold), 45 minutes per day, in the morning before the exercise&#xD;
      rehabilitation programme, for 3 weeks, 5 days per week. Control group (group SHAM): the&#xD;
      stimulation placebo will be delivered according to the same modalities as for the TENS group&#xD;
      but with a voltage level that vanishes automatically after 10 seconds of stimulation.&#xD;
&#xD;
      15 days of interventions (TENS or SHAM) between J0 and J23, End of study for patient at&#xD;
      J24-J25, two days for the last analyses who are the same of inclusion's visit J0.&#xD;
&#xD;
      Primary outcome: walking distance (metres) measured on a treadmill with a standardized&#xD;
      protocol. Secondary outcomes: transcutaneous oxygen pressure (TcPO2) measured during a&#xD;
      Strandness exercise test, peak oxygen uptake (VO2 peak) (ml.min.kg-1), endothelial function&#xD;
      (EndoPAT®), ankle-brachial pressure index, body mass index, lipid profile (LDL-C, HDL-C,&#xD;
      Triglycerides), fasting glycaemia, HbA1c, WELCH questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>walking distance without pain (in meters)</measure>
    <time_frame>Change between J0 and J25 (15 days)</time_frame>
    <description>the evolution of the claudication distance between the start and the end of the study (1 session of TENS each day , 15 days in total) in the two intervention group (TENS vs SHAM). Measure of change between inclusion and end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximal oxygen consumption (VO2peak in ml.min)</measure>
    <time_frame>Change between J0 and J25 (15 days)</time_frame>
    <description>maximal oxygen consumption (VO2peak in ml.min) Measure of change between inclusion and end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>1 - TENS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - SHAM group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.</description>
    <arm_group_label>1 - TENS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SHAM Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.</description>
    <arm_group_label>2 - SHAM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral Leriche stage II PAD, admitted to cardiovascular Rehabilitation Unit&#xD;
&#xD;
          -  Men or women&#xD;
&#xD;
          -  Able to take part in an out-patient rehabilitation programme&#xD;
&#xD;
          -  Clinically stable&#xD;
&#xD;
          -  Sedentary&#xD;
&#xD;
          -  Provided informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ward of court&#xD;
&#xD;
          -  Walking disorders related to orthopaedic or neuromuscular disease&#xD;
&#xD;
          -  Participation in a structured physical reconditioning programme in the month before&#xD;
             the study&#xD;
&#xD;
          -  Renal insufficiency requiring dialysis&#xD;
&#xD;
          -  Known and documented myopathy&#xD;
&#xD;
          -  Progressive cancer&#xD;
&#xD;
          -  Associated progressive disease causing a deterioration in general health&#xD;
&#xD;
          -  Participation in another research protocol&#xD;
&#xD;
          -  Skin disorder making it impossible to use TENS&#xD;
&#xD;
          -  Absolute contra-indication to physical activity&#xD;
&#xD;
          -  Presence of pacemaker / defibrillator&#xD;
&#xD;
          -  Pregnant women in the 1st trimester / 12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc LABRUNEE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc LABRUNEE, MD</last_name>
    <phone>05 61 32 21 03</phone>
    <phone_ext>33</phone_ext>
    <email>labrunee.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarisse BELVISI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de Saint-Orens</name>
      <address>
        <city>Saint-Orens de Gameville</city>
        <zip>31650</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital (CHU de Toulouse)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc LABRUNEE, MD</last_name>
      <phone>05 61 32 21 03</phone>
      <phone_ext>+33</phone_ext>
      <email>labrunee.m@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Arnaud LENDRIEUX</last_name>
      <phone>5 61 77 83 50</phone>
      <phone_ext>+33</phone_ext>
      <email>lendrieux.a@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marc LABRUNEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral artery disease</keyword>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>walking ability</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

